416 related articles for article (PubMed ID: 19060540)
1. Proliferation signal inhibitors and cardiac allograft vasculopathy.
Raichlin E; Kushwaha SS
Curr Opin Organ Transplant; 2008 Oct; 13(5):543-50. PubMed ID: 19060540
[TBL] [Abstract][Full Text] [Related]
2. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
3. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
Eisen H; Kobashigawa J; Starling RC; Valantine H; Mancini D
Transplant Proc; 2005 May; 37(4 Suppl):4S-17S. PubMed ID: 15809102
[TBL] [Abstract][Full Text] [Related]
4. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.
Chapman JR; Valantine H; Albanell J; Arns WA; Campistol JM; Eisen H; Frigerio M; Lehmkuhl H; Marcen R; Morris R; Nashan B; Pascual J; Pohanka E; Segovia J; Zuckermann A
Transplant Proc; 2007 Dec; 39(10):2937-50. PubMed ID: 18089298
[TBL] [Abstract][Full Text] [Related]
5. Can mTOR inhibitors reduce the risk of late kidney allograft failure?
Ponticelli C
Transpl Int; 2008 Jan; 21(1):2-10. PubMed ID: 17635837
[TBL] [Abstract][Full Text] [Related]
6. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.
Delgado JF; Manito N; Segovia J; Almenar L; Arizón JM; Campreciós M; Crespo-Leiro MG; Díaz B; González-Vílchez F; Mirabet S; Palomo J; Roig E; de la Torre JM
Transplant Rev (Orlando); 2009 Apr; 23(2):69-79. PubMed ID: 19298938
[TBL] [Abstract][Full Text] [Related]
7. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Valantine H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
[TBL] [Abstract][Full Text] [Related]
8. Medication management of cardiac allograft vasculopathy after heart transplantation.
Hollis IB; Reed BN; Moranville MP
Pharmacotherapy; 2015 May; 35(5):489-501. PubMed ID: 26011142
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression for heart transplantation: where are we now?
Kobashigawa JA; Patel JK
Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):203-12. PubMed ID: 16568129
[TBL] [Abstract][Full Text] [Related]
10. Proliferation signal inhibitors in cardiac transplantation.
Gustafsson F; Ross HJ
Curr Opin Cardiol; 2007 Mar; 22(2):111-6. PubMed ID: 17284989
[TBL] [Abstract][Full Text] [Related]
11. Treatment and prophylaxis of cardiac allograft vasculopathy.
Wang SS
Transplant Proc; 2008 Oct; 40(8):2609-10. PubMed ID: 18929815
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
15. Chronic allograft nephropathy--a clinical syndrome: early detection and the potential role of proliferation signal inhibitors.
Campistol JM; Boletis IN; Dantal J; de Fijter JW; Hertig A; Neumayer HH; Oyen O; Pascual J; Pohanka E; Ruiz JC; Scolari MP; Stefoni S; Serón D; Sparacino V; Arns W; Chapman JR
Clin Transplant; 2009; 23(6):769-77. PubMed ID: 19719730
[TBL] [Abstract][Full Text] [Related]
16. [Benefits of proliferation signal inhibitors beyond immunosuppression. Vascular protection and experience in heart transplantation].
Caillard S
Nephrol Ther; 2009 Dec; 5 Suppl 6():S379-84. PubMed ID: 20129449
[TBL] [Abstract][Full Text] [Related]
17. Evidence for immunosuppression in lung transplantation.
Hopkins PM; McNeil K
Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
[TBL] [Abstract][Full Text] [Related]
18. Use of rapamycin slows progression of cardiac transplantation vasculopathy.
Mancini D; Pinney S; Burkhoff D; LaManca J; Itescu S; Burke E; Edwards N; Oz M; Marks AR
Circulation; 2003 Jul; 108(1):48-53. PubMed ID: 12742978
[TBL] [Abstract][Full Text] [Related]
19. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy.
Bayliss J; Bailey M; Leet A; Stein AN; Thomson NM; McLean CA
Transplantation; 2008 Oct; 86(7):991-7. PubMed ID: 18852667
[TBL] [Abstract][Full Text] [Related]
20. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
Viganò M; Tuzcu M; Benza R; Boissonnat P; Haverich A; Hill J; Laufer G; Love R; Parameshwar J; Pulpón LA; Renlund D; Abeywickrama K; Cretin N; Starling RC; Eisen HJ;
J Heart Lung Transplant; 2007 Jun; 26(6):584-92. PubMed ID: 17543781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
